Chronic Obstr Pulm Dis. 2022 Oct 31. doi: 10.15326/jcopdf.2022.0326. Online ahead of print.
ABSTRACT
INTRODUCTION: Antiplatelet therapy has been associated with fewer exacerbations and reduced respiratory symptoms in COPD. Whether platelet activation is associated with respiratory symptoms in COPD is unknown.
METHODS: Former smokers with spirometry-confirmed COPD had urine 11-dehydro-thromboxane B2 (11dTxB2), plasma soluble CD40L (sCD40L) and soluble P-selectin (sP-selectin) repeatedly measured during a 6-9-month study period. Multivariate mixed-effects models adjusted for demographics, clinical characteristics, and medication use evaluated the association of each biomarker with respiratory symptoms, health status, and quality of life.
RESULTS: Among 169 participants (average age 66.5±8.2 years, 51.5% female, 47.5±31 pack-years, FEV1 percent predicted 53.8±17.1), a 100% increase in 11dTxB2 was associated with worse respiratory symptoms reflected by higher scores on the COPD Assessment Test (β 0.77, 95% confidence interval [CI]: 0.11-1.4), Ease of Cough and Sputum Clearance Questionnaire (ECSC) β 0.77, 95%CI: 0.38-1.2, worse health status (Clinical COPD Questionnaire [CCQ] β 0.13, 95%CI: 0.03-0.23) and worse quality of life (St. George’s Respiratory Questionnaire [SGRQ] β 1.9, 95%CI: 0.39-3.4). No statistically significant associations were observed for sCD40L or sP-selectin. There was no consistent statistically significant effect modification of the relationship between urine 11dTxB2 and respiratory outcomes by history of cardiovascular disease, subclinical coronary artery disease, antiplatelet therapy, or COPD severity.
CONCLUSIONS: In stable moderate-severe COPD, elevated urinary 11-dehydro-thromboxane B2, a metabolite of the platelet activation product thromboxane A2, was associated with worse respiratory symptoms, health status, and quality of life.
PMID:36367951 | DOI:10.15326/jcopdf.2022.0326
